Q-omics provides the consensus-scored FRRS1 profile across patient tissues and cancer cell-line models. FRRS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LGG. Among the 18 cancer types available for tumor–normal comparison, FRRS1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FRRS1 RNA expression shows 19,338 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LGG, HNSC, and THYM as cancer lineages where FRRS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRRS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRRS1 survival associations across molecular data types. FRRS1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRRS1 RNA expression–survival associations across cancer types. High FRRS1 expression shows unfavorable associations in LGG, KICH, BLCA, KIRP and LUAD, but favorable associations in KIRC. The LGG Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LGG as the clearest survival context for FRRS1 RNA expression.
This table summarizes FRRS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for FRRS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRRS1 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, BLCA, KIRC and LUSC. The HNSC box plot shows higher FRRS1 RNA expression in tumor versus normal tissue (log2 FC = +1.130, t-test p < 0.001).
This table shows molecular features associated with FRRS1 in patient tissues and cancer cell lines. In patient samples, FRRS1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FRRS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_NSCLC_LUSC.
